Shingles vaccine lowers risk of heart disease for 8 years, study finds
Getting a shingles vaccine may help with more than the viral infection that causes painful rashes — new research shows it can also lower the risk of heart disease.
In the study, published Monday in the European Heart Journal, researchers found people given the shot had a 23% lower risk of cardiovascular events, including stroke, heart failure and coronary heart disease, for up to 8 years.
The study examined more than 1 million people aged 50 or older with data from 2012 onward. The protective effect was particularly prominent in men, people under 60 and those who smoke, drink or aren't active, the study found.
Dong Keon Yon, a professor from the Kyung Hee University College of Medicine in Seoul, South Korea, who led the study, said in a news release that there are several reasons why the shingles vaccine may help reduce heart disease.
"A shingles infection can cause blood vessel damage, inflammation and clot formation that can lead to heart disease. By preventing shingles, vaccination may lower these risks," he explained. "Our study found stronger benefits in younger people, probably due to a better immune response, and in men, possibly due to differences in vaccine effectiveness."
The vaccine analyzed was a live zoster vaccine, which contains a weakened form of the varicella zoster virus that causes shingles. Not everyone can take the live vaccine, however, including those with certain immune system conditions, and some countries are replacing it with non-live, recombinant vaccines.
The United States is among the countries that use the new vaccine, Shingrix, which was introduced in 2017. The vaccine, manufactured by GlaxoSmithKline, is more than 90% effective in preventing shingles. It replaced the previously used single-dose live vaccine, Zostavax, by Merck.
"Since the live zoster vaccine is not suitable for everyone, more research on the recombinant vaccine is needed" to confirm if it has a similar impact, Yon said, adding that the study also does not establish a direct causal relationship.
The Centers for Disease Control and Prevention already recommends everyone get the two-dose shingles vaccine starting at age 50.
Shingles, which causes a painful rash, is caused by the same virus behind chickenpox. The virus lies dormant in people who've had chickenpox and years later can reactivate as shingles. The risk of shingles also increases with age, particularly in those older than 50, according to the CDC.
This isn't the first time a shingles vaccine has been shown to have other possible health benefits. A study last year found latest shingles shot also seems to delay the onset of dementia, a memory-impairing condition.
In that study, published in Nature Medicine in July, researchers found people who got the vaccine lived, on average, an additional 164 days without a dementia diagnosis compared to those who received the previous shingles vaccines.
"The fact that we have a vaccine that's already approved, already out there, covered by insurance, super easy to get. The fact that that is showing this kind of level of protection is really promising for a lot," Dr. Céline Gounder, CBS News medical contributor and editor-at-large for public health at KFF Health News, said on "CBS Mornings" at the time.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
27-05-2025
- Medscape
Newly Approved Mepolizumab Mitigates COPD Exacerbations
Adding mepolizumab to inhaled triple therapy significantly improved exacerbation outcomes compared with placebo in adults with chronic obstructive pulmonary disease (COPD), based on data from the MATINEE study presented at the American Thoracic Society (ATS) 2025 International Conference. Based on these findings, mepolizumab is newly approved by the US Food and Drug Administration for the treatment of COPD according to manufacturer GlaxoSmithKline. 'This decision is good news for patients because it allows more options for care, and it is good news for the future of COPD treatment in that there are now more options showing targets previously not identified that can improve patient outcomes,' said co-author Gerard J. Criner, MD, of the Lewis Katz School of Medicine at Temple University, Philadelphia, in a statement following the approval. Patients with COPD and type 2 inflammation are at an increased risk for frequent and severe exacerbations that may require hospitalization or emergency department visits, Alberto Papi, MD, of the University of Ferrara, Ferrara, Italy, and colleagues wrote in their abstract. Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in patients with COPD regardless of the history or severity of exacerbations in a phase 3 study known as MATINEE, the researchers wrote. In the study, the researchers randomized 804 adults aged 40 years or older with COPD to a subcutaneous dose of 100 mg of mepolizumab every 4 weeks for 52-104 weeks, or a placebo, in addition to the inhaled triple therapy of a fluticasone propionate dose of at least 500 μg/d or the equivalent, plus dual long-acting bronchodilators. Approximately 21% of the patients had a history of severe exacerbations in the past years. The mean age of the participants was approximately 66 years, and at least two thirds were men. Overall, patients treated with mepolizumab had a 21% reduced annualized rate of moderate to severe exacerbations compared with patients treated with placebo, with rate ratios of 0.75 and 0.79 for subgroups with and without a history of severe exacerbations, respectively. In addition, patients with a history of severe exacerbations had a 32% reduced rate of exacerbations requiring an emergency department visit or hospital stay. The results were durable as well, the researchers noted. The significant difference in exacerbation rates between patients treated with mepolizumab and those treated with placebo was observed at 1 year and continued for up to 104 weeks of treatment. The incidence of adverse events and serious adverse events was similar in the mepolizumab and placebo groups, the most common of which was exacerbation of COPD (11% and 15% for serious adverse events in the mepolizumab and placebo groups, respectively). Takeaways and Next Steps The researchers were surprised that mepolizumab's significant clinical impact on exacerbation reduction extended to such a broad group of patients with COPD, including those who did or did not have chronic bronchitis, and those with evidence of emphysema, Criner said in an interview. 'That mepolizumab could decrease emergency room visits and hospitalization is a significant benefit for patients,' he added. Mepolizumab made all its primary and key secondary end points with a robust safety profile, said Criner. 'Patients with COPD who have type 2 inflammation can benefit from biologic therapy, regardless of the severity of underlying airflow obstruction with or without the absence of chronic bronchitis or emphysema to reduce moderate and severe exacerbations,' he said. Additional research should target different pathways and patients who have inflammation with COPD, such as types 1 and 3, Criner noted. Approval Sparks Enthusiasm 'I'm excited to have another option to treat COPD patients who have elevated eosinophils and frequent exacerbations,' said study co-author Meilan Han, MD, of the University of Michigan, Ann Arbor, Michigan, in an interview. 'I'd like additional research to help us understand which patients experience the best response in terms of lung function and symptoms,' she added. The approval will change care of patients with COPD who are already maximized on inhaler therapies and continue to have exacerbations, 'as this is the only biologic approved for patients with blood eosinophils <= 300 cells/µL,' said Arianne K. Baldomero, MD, a pulmonologist and assistant professor of medicine at the University of Minnesota, Minneapolis, in an interview. 'The cost could be prohibitive (annual cost is almost $50,000 per year); so patients should explore insurance coverage, manufacturer assistance programs, nonprofit financial support, and discount cards to reduce their out-of-pocket expenses for mepolizumab,' she said. 'The MATINEE study was important because, despite optimal triple inhaler therapy, many high-risk patients continue to experience frequent COPD exacerbations. This trial evaluated whether adding a new therapy can further reduce exacerbations in this high-risk COPD population,' said Baldomero. However, as with other biologics, when or whether mepolizumab can be safely discontinued, and whether the risk for COPD exacerbations will return upon stopping remains unclear, said Baldomero. 'Additionally, there is limited evidence to guide whether inhaler therapies can be withdrawn while on biologics, and more research is needed to determine optimal treatment duration,' she said. Expanded MATINEE Findings Offer More Insights Several other studies of MATINEE findings were presented at the meeting. In one study, data showed that mepolizumab reduced exacerbations in patients with cardiovascular comorbidities compared with placebo. Post hoc analyses of data from the MATINEE study also were presented at the meeting to examine the effectiveness of mepolizumab in various subgroups. In one post hoc analysis, patients treated with mepolizumab had lower mean healthcare resource use per exacerbation in terms of emergency department visits, urgent care/outpatient clinic visits, and days in intensive care than patients treated with placebo. Another analysis of MATINEE study data showed that, compared with placebo, mepolizumab significantly improved exacerbation rates in patients with severely restricted airflow based on the GOLD criteria. An additional post hoc analysis showed that, compared with placebo, mepolizumab's association with improved exacerbation rates was consistent regardless of duration of COPD. Mepolizumab has been developed for the treatment of a range of IL-5 mediated diseases associated with type 2 inflammation and is also approved for use in the United States and Europe for severe asthma, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyps, according to manufacturer GlaxoSmithKline. The MATINEE study was funded by GlaxoSmithKline. Criner disclosed receiving consulting fees and research funds from GlaxoSmithKline. Han disclosed serving as a consultant for GlaxoSmithKline and multiple relationships with pharmaceutical companies outside of the MATINEE study.
Yahoo
26-05-2025
- Yahoo
Rising Demand for Preventive Healthcare Spurs Growth in Qatar's Supplement Sector - A $70.48 Million Market by 2030
The Qatar Dietary Supplements Market is set to grow from USD 48.19 Million in 2024 to USD 70.48 Million by 2030, driven by rising health consciousness, affluence, and a focus on preventive healthcare. Key players include Pfizer, Abbott, and GlaxoSmithKline. Challenges include regulatory barriers, while trends emphasize personalized nutrition. Qatari Dietary Supplements Market Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Qatar Dietary Supplements Market by Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The dietary supplements market in Qatar is on a robust growth trajectory, valued at USD 48.19 million in 2024 and anticipated to reach USD 70.48 million by 2030, with a CAGR of 6.5%. This expansion is propelled by rising health consciousness, a shift towards preventive healthcare, and increasing affluence. As a burgeoning sector in the Middle East, Qatar's market is witnessing heightened momentum due to a growing awareness of nutrition's role in managing chronic diseases, wellness, and overall health enhancement. Factors such as the rising prevalence of obesity and diabetes are escalating the demand for supplements targeting weight management, metabolic health, and immune support. Concurrently, consumer preferences are shifting towards natural, personalized, and functional products. These trends, along with government-supported health initiatives and a burgeoning retail framework, present opportunities for both established and emerging players to cater to Qatar's evolving nutritional demands. Key Market Drivers Increasing Health Consciousness:The surge in health consciousness within Qatar's population is significantly driving the dietary supplements market. Consumers are increasingly focusing on wellness and disease prevention, fueling interest in supplements that enhance immunity, energy, weight management, and general health. The country's growing burden of chronic diseases, such as obesity and diabetes, underscores this trend. National efforts that integrate traditional wellness practices with modern health systems further bolster awareness and accessibility, making supplements a staple in daily wellness routines. Key Market Challenges Strict Regulatory Environment and Compliance Barriers: The dietary supplements sector in Qatar faces challenges from a stringent regulatory environment enforced by the Ministry of Public Health. Compliance involves comprehensive safety and quality standards, including detailed product registration and accurate labeling. These regulatory demands can delay product launches and restrict marketing agility, posing hurdles particularly for small and medium-sized enterprises lacking the infrastructure to navigate compliance requirements. Key Market Trends Personalized Nutrition and Supplementation: Personalized nutrition solutions are a growing trend in Qatar's dietary supplements market. Consumers are increasingly moving away from generic products in favor of customized regimens tailored to individual health profiles. This trend is particularly strong among affluent, health-conscious consumers in urban areas like Doha. Personalized solutions incorporate diagnostic tools such as DNA tests and lifestyle assessments to create targeted plans, supported by tech integration that enhances long-term engagement. The market's focus on digital health and preventive care aligns with the increasing demand for personalization in the wellness industry, a trend expected to gain further traction. Key Players Profiled 3A Pharma Natures & Bounty Natures Aid Fortex Nutraceuticals Geltec Co., Ltd Pfizer, Inc Holland & Barrett Abbott Laboratories, Inc. GlaxoSmithKline, Plc Olimp Labs Report Scope: By Product Type: Vitamin, Combination Dietary Supplements, Protein, Herbal Supplements, Fish Oil & Omega Fatty Acid, Others. By Form: Capsules, Tablets, Powder, Soft Gels, Liquid. By Distribution Channel: Pharmacies and Drug Stores, Online, Supermarkets and Hypermarkets, Others. By Application: Immunity, General Health, Energy & Weight Management, Bone & Joint Health, Others. By End User: Adults, Geriatric, Pregnant Females, Children, Infants. By Region: Doha, Al Rayyan, Al Wakra, Umm Slal, Rest of Qatar. Key Attributes: Report Attribute Details No. of Pages 85 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $48.19 Million Forecasted Market Value (USD) by 2030 $70.48 Million Compound Annual Growth Rate 6.5% Regions Covered Qatar For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Qatari Dietary Supplements Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
26-05-2025
- Yahoo
Rising Demand for Preventive Healthcare Spurs Growth in Qatar's Supplement Sector - A $70.48 Million Market by 2030
The Qatar Dietary Supplements Market is set to grow from USD 48.19 Million in 2024 to USD 70.48 Million by 2030, driven by rising health consciousness, affluence, and a focus on preventive healthcare. Key players include Pfizer, Abbott, and GlaxoSmithKline. Challenges include regulatory barriers, while trends emphasize personalized nutrition. Qatari Dietary Supplements Market Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Qatar Dietary Supplements Market by Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The dietary supplements market in Qatar is on a robust growth trajectory, valued at USD 48.19 million in 2024 and anticipated to reach USD 70.48 million by 2030, with a CAGR of 6.5%. This expansion is propelled by rising health consciousness, a shift towards preventive healthcare, and increasing affluence. As a burgeoning sector in the Middle East, Qatar's market is witnessing heightened momentum due to a growing awareness of nutrition's role in managing chronic diseases, wellness, and overall health enhancement. Factors such as the rising prevalence of obesity and diabetes are escalating the demand for supplements targeting weight management, metabolic health, and immune support. Concurrently, consumer preferences are shifting towards natural, personalized, and functional products. These trends, along with government-supported health initiatives and a burgeoning retail framework, present opportunities for both established and emerging players to cater to Qatar's evolving nutritional demands. Key Market Drivers Increasing Health Consciousness:The surge in health consciousness within Qatar's population is significantly driving the dietary supplements market. Consumers are increasingly focusing on wellness and disease prevention, fueling interest in supplements that enhance immunity, energy, weight management, and general health. The country's growing burden of chronic diseases, such as obesity and diabetes, underscores this trend. National efforts that integrate traditional wellness practices with modern health systems further bolster awareness and accessibility, making supplements a staple in daily wellness routines. Key Market Challenges Strict Regulatory Environment and Compliance Barriers: The dietary supplements sector in Qatar faces challenges from a stringent regulatory environment enforced by the Ministry of Public Health. Compliance involves comprehensive safety and quality standards, including detailed product registration and accurate labeling. These regulatory demands can delay product launches and restrict marketing agility, posing hurdles particularly for small and medium-sized enterprises lacking the infrastructure to navigate compliance requirements. Key Market Trends Personalized Nutrition and Supplementation: Personalized nutrition solutions are a growing trend in Qatar's dietary supplements market. Consumers are increasingly moving away from generic products in favor of customized regimens tailored to individual health profiles. This trend is particularly strong among affluent, health-conscious consumers in urban areas like Doha. Personalized solutions incorporate diagnostic tools such as DNA tests and lifestyle assessments to create targeted plans, supported by tech integration that enhances long-term engagement. The market's focus on digital health and preventive care aligns with the increasing demand for personalization in the wellness industry, a trend expected to gain further traction. Key Players Profiled 3A Pharma Natures & Bounty Natures Aid Fortex Nutraceuticals Geltec Co., Ltd Pfizer, Inc Holland & Barrett Abbott Laboratories, Inc. GlaxoSmithKline, Plc Olimp Labs Report Scope: By Product Type: Vitamin, Combination Dietary Supplements, Protein, Herbal Supplements, Fish Oil & Omega Fatty Acid, Others. By Form: Capsules, Tablets, Powder, Soft Gels, Liquid. By Distribution Channel: Pharmacies and Drug Stores, Online, Supermarkets and Hypermarkets, Others. By Application: Immunity, General Health, Energy & Weight Management, Bone & Joint Health, Others. By End User: Adults, Geriatric, Pregnant Females, Children, Infants. By Region: Doha, Al Rayyan, Al Wakra, Umm Slal, Rest of Qatar. Key Attributes: Report Attribute Details No. of Pages 85 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $48.19 Million Forecasted Market Value (USD) by 2030 $70.48 Million Compound Annual Growth Rate 6.5% Regions Covered Qatar For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Qatari Dietary Supplements Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
